<DOC>
	<DOCNO>NCT01898156</DOCNO>
	<brief_summary>This Phase 1/2 study design ass follow : safety tolerability BIW-8962 , Dose Limiting Toxicities ( DLTs ) , Maximum Tolerated Dose ( MTD ) , Recommended Phase 2 Dose ( RP2D ) Phase 1 subject advanced/recurrent lung cancer mesothelioma preliminary efficacy Phase 2 subject advanced/recurrent Small Cell Lung Cancer .</brief_summary>
	<brief_title>Two-Part , Open-Label , Multi-Center , Phase 1/2 Study BIW-8962 Monotherapy Subjects With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Phase 1 : histopathologicaldocumented , measurable nonmeasurable unresectable , advanced primary recurrent SCLC , NSCLC mesothelioma Phase 2 : measurable , unresectable advanced recurrent SCLC A life expectancy &gt; 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status score 01 study entry Echocardiogram multigated acquisition ( MUGA ) scan leave ventricular ejection fraction ( LVEF ) ≥ 50 % , ≥ institution 's establish low limit normal Adequate hematologic , hepatic , renal lung function Subject receive cytotoxic anticancer chemotherapy , orally available signal pathwaytargeted therapy , hormonal therapy , radiotherapy , immunotherapy , investigational agent within 3 week prior first dose Subject receive monoclonal antibody within 4 week first dose Major surgery within 4 week prior first dose Known symptomatic brain metastasis Clinically significant cardiovascular disease Leptomeningeal disease Uncontrolled intercurrent illness include ongoing active infection , uncontrolled diabetes , etc Known HIV disease acquire immunodeficiency syndromerelated illness A psychiatric illness , disability social situation Hypersensitivity reaction monoclonal antibody , therapeutic proteins A history primary brain/CNS malignancy Neurological paraneoplastic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>